| Followers | 4 |
| Posts | 723 |
| Boards Moderated | 0 |
| Alias Born | 12/02/2009 |
Sunday, July 17, 2011 4:38:22 PM
I was wondering because I had an order in at market open to sell 10K @.34. The bid stayed at .34 for about six minutes. I believe two trades went off above .34 and the bid remained at .34. Next thing I know the bid dropped to approx. .32 and I never got the order executed. The rules with the BB stocks are a world of their own but it did concern me that I couldn't get 10K shares off at the bid while the bid remained at my price for so long. I've also noticed there are unusually long lags to get an execution whenever I trade more than 10K shares. Anyone have a plausible explanation? Have a great rest of the weekend all longs.
Recent SNGX News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/03/2026 04:15:15 AM
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy • PR Newswire (US) • 04/02/2026 11:30:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:13:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:11:25 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:09:30 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:08:14 PM
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:30:00 AM
- Soligenix secures EU orphan drug designation for Behçet’s disease therapy • IH Market News • 03/26/2026 02:15:07 PM
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 03/26/2026 11:30:00 AM
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 • PR Newswire (US) • 03/23/2026 11:30:00 AM
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" • PR Newswire (US) • 03/19/2026 11:30:00 AM
- Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency • PR Newswire (US) • 03/10/2026 11:30:00 AM
- Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 02/26/2026 12:30:00 PM
- Soligenix to Present at BIO Investment & Growth Summit • PR Newswire (US) • 02/24/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:05:19 PM
- Soligenix Details Recent Progress and Upcoming Milestones • PR Newswire (US) • 02/12/2026 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/23/2026 09:31:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2026 09:05:35 PM
- Soligenix Shares Jump on Encouraging Data for Behçet’s Disease Therapy • IH Market News • 12/18/2025 03:30:21 PM
- Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) • PR Newswire (US) • 12/18/2025 12:30:00 PM
